Literature DB >> 19528277

Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.

Dao Van Hoang Nguyen1, Quoc Phuc Nguyen, Ngoa Dang Nguyen, Thuy Thi Thanh Le, The Duy Nguyen, Duy Ngoc Dinh, Thanh Xuan Nguyen, Dai Bui, Marina Chavchich, Michael D Edstein.   

Abstract

Compared to healthy subjects, malaria patients show a reduction in the mean oral clearance (1.19 versus 5.87 liters/h/kg of body weight) and apparent volume of distribution (1.47 versus 8.02 liters/kg) of dihydroartemisinin in Vietnamese patients following treatment with dihydroartemisinin-piperaquine (Artekin) for uncomplicated Plasmodium falciparum. Dihydroartemisinin is responsible for most of the ex vivo antimalarial activity of dihydroartemisinin-piperaquine.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19528277      PMCID： PMC2715592          DOI： 10.1128/AAC.01717-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum.

Authors:  Quinton L Fivelman; Ipemida S Adagu; David C Warhurst
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.

Authors:  Quinton L Fivelman; Ipemida S Adagu; David C Warhurst
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

3.  Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria.

Authors:  T Q Binh; K F Ilett; K T Batty; T M Davis; N C Hung; S M Powell; L T Thu; H V Thien; H L Phuöng; V D Phuong
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

4.  Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.

Authors:  P Newton; Y Suputtamongkol; P Teja-Isavadharm; S Pukrittayakamee; V Navaratnam; I Bates; N White
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Authors:  A Ratcliff; H Siswantoro; E Kenangalem; R Maristela; R M Wuwung; F Laihad; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

6.  Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Nguyen Xuan Thanh; Bui Dai; Jason P Geue; Russell S Addison; Thomas Travers; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

7.  Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria.

Authors:  Harin Karunajeewa; Chiv Lim; Te-Yu Hung; Kenneth F Ilett; Mey Bouth Denis; Doung Socheat; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

8.  Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects.

Authors:  Trong Chinh Nguyen; Ngoc Quang Nguyen; Xuan Thanh Nguyen; Dai Bui; Thomas Travers; Michael D Edstein
Journal:  Am J Trop Med Hyg       Date:  2008-10       Impact factor: 2.345

9.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

Authors:  Te-Yu Hung; Timothy M E Davis; Kenneth F Ilett; Harin Karunajeewa; Sean Hewitt; Mey Bouth Denis; Chiv Lim; Doung Socheat
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

10.  Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.

Authors:  J Tarning; E A Ashley; N Lindegardh; K Stepniewska; L Phaiphun; N P J Day; R McGready; M Ashton; F Nosten; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191
View more
  24 in total

1.  Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Authors:  Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Sommethy Sok; Winita Ta-Aksorn; Chanikarn Kodchakorn; Sut-Thang Pann; Soklyda Chann; Mali Ittiverakul; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mary So; Theng Youdaline; Erin Milner; Mariusz Wojnarski; Charlotte Lanteri; Jessica Manning; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

3.  Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.

Authors:  Marcus J Rijken; Rose McGready; Aung Phae Phyo; Niklas Lindegardh; Joel Tarning; Natthapon Laochan; Hla Hla Than; Oh Mu; Aye Kyi Win; Pratap Singhasivanon; Nicholas White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

4.  A small amount of fat does not affect piperaquine exposure in patients with malaria.

Authors:  Anna Annerberg; Khin Maung Lwin; Niklas Lindegardh; Sakchai Khrutsawadchai; Elizabeth Ashley; Nicholas P J Day; Pratap Singhasivanon; Joel Tarning; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

5.  pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine.

Authors:  M I Veiga; P E Ferreira; M Malmberg; L Jörnhagen; A Björkman; F Nosten; J P Gil
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

6.  Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers.

Authors:  Huixiang Liu; Hongchang Zhou; Tianyu Cai; Aijuan Yang; Meitong Zang; Jie Xing
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

Authors:  N C Sambol; L Yan; D J Creek; S A McCormack; E Arinaitwe; V Bigira; H Wanzira; A Kakuru; J W Tappero; N Lindegardh; J Tarning; F Nosten; F T Aweeka; S Parikh
Journal:  Clin Pharmacol Ther       Date:  2015-05-02       Impact factor: 6.875

8.  Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Authors:  Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh
Journal:  J Infect Dis       Date:  2013-02-27       Impact factor: 5.226

9.  Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.

Authors:  Katherine Kay; Eva Maria Hodel; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

10.  The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites.

Authors:  Marina Chavchich; Karin Van Breda; Kerryn Rowcliffe; Thierry T Diagana; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.